|  |
| --- |
| **Table S3. Associations of week 48 clinical response with baseline and week 16 biomarker levels.**  |
|  |  | **Week 48 clinical response, fold (R/NR)** † |
| **Biomarker \*** |  | **Placebo** |  | **Golimumab** |
|  | **No Flare** | **JIA-ACR30** | **Remission** | **Inactive Disease** |  | **No Flare** | **JIA-ACR30** | **Remission** | **Inactive Disease** |
| ***Week 0 levels*** |  |  |  |  |  |  |  |  |  |  |
| C-reactive protein |  | **-3.85** | **-4.94** | **-7.41** | **-4.07** |  | 1.37 | 1.56 | -2.49 | 1.06 |
| Interleukin-6 |  | **-2.74** | **-2.98** | **-5.71** | **-3.46** |  | 1.44 | 1.69 | -1.31 | -1.08 |
| Serum amyloid A |  | **-3.21** | **-3.60** | **-5.29** | **-3.19** |  | -1.40 | -1.19 | -1.01 | -1.20 |
| Fibroblast Growth Factor, basic |  | -1.49 | -1.33 | **-3.79** | **-2.05** |  | 1.11 | -1.01 | 1.33 | -1.01 |
| Interleukin-8 |  | -1.08 | -1.07 | -1.04 | -1.33 |  | -1.09 | 1.06 | -1.17 | -1.12 |
| Interferon-induced protein-10 |  | -1.39 | -1.43 | -1.22 | -1.27 |  | -1.00 | 1.04 | -1.59 | -1.58 |
| Vascular Endothelial Growth Factor |  | **-1.69** | **-1.61** | **-2.21** | **-1.62** |  | 1.08 | 1.24 | 1.04 | 1.02 |
| Erythrocyte Sedimentation Rate |  | **-1.45** | **-1.47** | **-1.84** | **-1.58** |  | 1.15 | 1.44 | -2.60 | 1.14 |
| Blood Neutrophils (density) |  | -1.17 | -1.19 | **-1.39** | **-1.27** |  | -1.05 | -1.03 | 1.05 | -1.02 |
| Blood Leukocytes (density) |  | -1.11 | -1.13 | -1.22 | -1.15 |  | -1.01 | 1.02 | 1.05 | 1.01 |
| ***Week 16 levels*** |  |  |  |  |  |  |  |  |  |  |
| C-reactive protein |  | -2.46 | -2.41 | -4.08 | **-3.80** |  | -1.01 | 1.04 | -3.63 | -2.03 |
| Interleukin-6 |  | **-2.13** | **-2.24** | **-2.74** | **-2.91** |  | -1.04 | -1.05 | **-3.50** | **-2.75** |
| Serum amyloid A |  | -1.48 | -1.41 | -2.27 | -1.78 |  | 1.06 | 1.15 | -1.20 | -1.64 |
| Fibroblast Growth Factor, basic |  | -1.02 | -1.03 | -2.09 | 1.09 |  | 1.46 | 1.20 | -1.06 | 1.37 |
| Interleukin-8 |  | **1.30** | 1.27 | -1.01 | 1.15 |  | 1.22 | 1.28 | -1.31 | 1.22 |
| Interferon-induced protein-10 |  | -1.44 | -1.44 | -1.79 | -1.48 |  | -1.09 | -1.10 | -1.34 | -1.30 |
| Vascular Endothelial Growth Factor |  | **-1.50** | -1.43 | -1.69 | -1.42 |  | -1.21 | -1.12 | -1.30 | -1.36 |
| Erythrocyte Sedimentation Rate |  | **-1.28** | **-1.33** | **-1.44** | **-1.24** |  | -1.18 | 1.01 | **-2.00** | **-1.24** |
| Blood Neutrophils (density) |  | -1.10 | -1.09 | -1.31 | -1.10 |  | **-1.23** | -1.20 | -1.00 | -1.13 |
| Blood Leukocytes (density) |   | -1.04 | -1.03 | -1.18 | -1.05 |   | -1.08 | -1.09 | 1.09 | -1.04 |
| \* Baseline and week 16 levels of indicated serum analyte or hematology parameter reported for those with p<0.05 for 'Yes' vs. 'No' for at least one of the week 48 response variables.† Fold for geometric mean of 'Yes' over geometric mean of 'No', for indicated biomarkers, reported for indicated week 48 response variable; values bolded and shaded when p<0.05.R = Responder. NR = Nonresponder. JIA-ACR30 = ≥30% improvement in Juvenile Idiopathic Arthritis-American College of Rheumatology response criteria  |